Press Releases

Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)

Novel proprietary EET platform extends Coya Therapeutics' pipeline beyond Neurodegenerative disorders to include autoimmune disorders and cancer while expanding Coya’s optionality for potential non-dilutive business development and strategic partnerships with companies seeking novel ways to deliver cargo/drugs in a targeted fashion.

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

Creative Biostructure Announces New Method for Producing CRAL-TRIO Domain-Containing Proteins Using Virus-Like Particles

Matexcel Launches New Line of Natural Extract Peptide Products for Research Use

Profacgen Announces New Technology for Membrane Protein Production

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

CD BioGlyco Launches Anti-glycan Antibody Development Services to Advance Biomedical Research

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

MERCY BIOANALYTICS ADDS MARKETING AND PORTFOLIO MANAGEMENT LEADERSHIP TO SUPPORT DIAGNOSTIC TEST DEVELOPMENT AND COMMERCIALIZATION

Mercy BioAnalytics, Inc. - a pioneer in extracellular vesicle-based liquid biopsies for early cancer detection - added two executives in marketing and portfolio management as it continues rapid development of its novel test portfolio and looks ahead to commercialization.

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Precision BioLogic’s Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S.

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new cryocheck™ Factor VIII Deficient Plasma with VWF in the U.S. The latest in Precision BioLogic’s family of factor deficient plasmas, cryocheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A. It has normal levels of von Willebrand factor (VWF) but both FVIII antigen and activity levels of less than 1%. The importance of FVIII antigen levels in the performance of FVIII deficient substrates was demonstrated in a study presented at ISTH 2021. "CRYOcheck Factor VIII Deficient Plasma with VWF offers labs a readily available and reliable alternative to congenital FVIII deficient plasmas. In fact, the product has already gained significant traction within the hemophilia research and pharmaceutical manufacturing community," says Paul Empey, President & CEO of Precision BioLogic.

PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services

Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications.

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

Dr. Joanna Barbara will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.